Read by QxMD icon Read

Chemotherapy executive function

D D Correa, J C Root, M Kryza-Lacombe, M Mehta, S Karimi, M L Hensley, N Relkin
Women with ovarian cancer often undergo chemotherapy involving multiple agents. However, little is known about treatment-related central neurotoxicity in this population. The goal of this cross-sectional study was to assess brain structure and function and neurocognitive abilities in patients with ovarian cancer following first-line chemotherapy. Eighteen patients with ovarian, peritoneal and fallopian tube cancer and eighteen healthy controls matched for gender, age and education participated in the study...
October 20, 2016: Brain Imaging and Behavior
Stephen A Sands, Brian T Harel, Mirko Savone, Kara Kelly, Veena Vijayanathan, Jennifer Greene Welch, Lynda Vrooman, Lewis B Silverman, Peter D Cole
PURPOSE: Neurocognitive impairment is frequently observed among acute lymphoblastic leukemia (ALL) survivors within the domains of intelligence, attention, processing speed, working memory, learning, and memory. However, few have investigated treatment-induced changes in neurocognitive function during the first months of treatment. Additionally, dysfunction during treatment may be preceded by changes in biomarkers measured within cerebrospinal fluid (CSF). Identification of acute declines in neurocognitive function, as well as predictive genotypes or biomarkers, could guide therapeutic trials of protective interventions...
October 10, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Hee Jung Yoo, Hyery Kim, Hyeon Jin Park, Dong Seok Kim, Young Shin Ra, Hee Young Shin
The neurocognitive function and quality of life of 58 Korean survivors of childhood medulloblastoma were assessed after surgery, cranial radiation and chemotherapy. All patients were evaluated with a battery of neurocognitive function tests and the Pediatric Functional Assessment of Cancer Therapy-Brain Tumor Survivors, which consists of self-report questionnaires on quality of life. The mean full-scale intelligence quotient (IQ), verbal IQ, and performance IQ scores were 90.2, 97.1, and 84.16, respectively...
November 2016: Journal of Korean Medical Science
Yin Ting Cheung, Noah D Sabin, Wilburn E Reddick, Deepa Bhojwani, Wei Liu, Tara M Brinkman, John O Glass, Scott N Hwang, Deokumar Srivastava, Ching-Hon Pui, Leslie L Robison, Melissa M Hudson, Kevin R Krull
BACKGROUND: Leukoencephalopathy is observed in some children undergoing chemotherapy for acute lymphoblastic leukaemia, although its effects on long-term outcomes is unknown. This study examines the associations between acute leukoencephalopathy and neurobehavioural, neurocognitive, and brain white matter imaging outcomes in long-term survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy without cranial radiation. METHODS: In this longitudinal analysis, we used data of children with acute lymphoblastic leukaemia at St Jude Children's Research Hospital (Memphis, TN, USA) who had been treated between June 1, 2000, and Oct 31, 2010...
October 2016: Lancet Haematology
Zhongyong Shi, Shifu Xiao, Xia Li
The current case describes a 78-year-old female with two previous episodes of major depression who presented with both symptoms of depression (amotivation and flattened affect) and typical symptoms of dementia (impaired memory and executive functioning). Even after a detailed clinical exam and neuropsychiatric testing, it remained difficult to definitively classify the diagnosis as either treatment-resistant depression or old-age dementia. After 8 weeks of inpatient treatment, including changing her reserpine-based antihypertensive medication, adjusting her antidepressants, and providing psychotherapy, her depressive and anxiety symptoms improved, but most of her cognitive symptoms persisted...
April 25, 2016: Shanghai Archives of Psychiatry
Ding Xia, Weiwei Lou, Kar-Ming Fung, Cole L Wolley, Mahmoud M Suhail, Hsueh-Kung Lin
A 52-year-old Hispanic male presented with hematuria and was later diagnosed with a large invasive high-grade urothelial cell carcinoma (UCC) of the urinary bladder, but with ambiguous pT1/pT2 staging regarding musclaris propria invasion by UCC. The conventional treatment including radical cystoprostatectomy followed by neoadjuvant chemotherapy with or without radiation therapy was presented. The patient decided to delay the standard therapy until a later stage, but elected to go through transurethral resection of bladder tumor (TURBT) without Bacillus Calmette-Guérin instillation...
August 16, 2016: Integrative Cancer Therapies
Charlene J Treanor, Una C McMenamin, Roisin F O'Neill, Chris R Cardwell, Mike J Clarke, Marie Cantwell, Michael Donnelly
BACKGROUND: It is estimated that up to 75% of cancer survivors may experience cognitive impairment as a result of cancer treatment and given the increasing size of the cancer survivor population, the number of affected people is set to rise considerably in coming years. There is a need, therefore, to identify effective, non-pharmacological interventions for maintaining cognitive function or ameliorating cognitive impairment among people with a previous cancer diagnosis. OBJECTIVES: To evaluate the cognitive effects, non-cognitive effects, duration and safety of non-pharmacological interventions among cancer patients targeted at maintaining cognitive function or ameliorating cognitive impairment as a result of cancer or receipt of systemic cancer treatment (i...
2016: Cochrane Database of Systematic Reviews
Cecilia Follin, Eva Marie Erfurth, Aki Johansson, Jimmy Lätt, Pia C Sundgren, Kai Österberg, Gabriella Spulber, Peter Mannfolk, Isabella M Björkman-Burtscher
Cranial radiotherapy is a known risk factor for neurocognitive impairment in survivors of childhood acute lymphoblastic leukemia (ALL). Understanding the nature of cognitive dysfunction during adulthood in ALL survivors is important as it has an impact on major life situations. Thirty-eight (21 women) ALL survivors were investigated 34 years after diagnosis. Median-age was 38 (27-46) years. All were treated with a CRT dose of 24Gy and 11 years (3-13) of complete hormone supplementation. Comparisons were made to 29 matched controls...
November 2016: Psychoneuroendocrinology
L Tao, H Lin, Y Yan, X Xu, L Wang, J Zhang, Y Yu
The aim of this study is to investigate chemotherapy-induced alterations in the functional framework of the brain, and probe the relationship between these changes and executive function impairments in breast cancer patients. Thirty-three breast cancer patients (BC) after receiving chemotherapy and 31 matched healthy controls (HC) were enrolled in this study. All participants received resting-state functional connectivity magnetic resonance imaging (rs-fcMRI) and neuropsychological background tests. The lower functional connectivity of the posterior cingulate cortex (PCC) was found in the left postcentral gyrus, left precentral gyrus, right superior temporal gyrus, right cingulate gyrus and right middle frontal gyrus...
July 19, 2016: European Journal of Cancer Care
Hannah R Wardill, Kimberley A Mander, Ysabella Za Van Sebille, Rachel J Gibson, Richard M Logan, Joanne M Bowen, Stephen T Sonis
Neurotoxicity is a common side effect of chemotherapy treatment, with unclear molecular mechanisms. Clinical studies suggest that the most frequent neurotoxic adverse events affect memory and learning, attention, concentration, processing speeds and executive function. Emerging preclinical research points toward direct cellular toxicity and induction of neuroinflammation as key drivers of neurotoxicity and subsequent cognitive impairment. Emerging data now show detectable levels of some chemotherapeutic agents within the CNS, indicating potential disruption of blood brain barrier integrity or transport mechanisms...
July 1, 2016: International Journal of Cancer. Journal International du Cancer
Lu Wang, Yunwen Yan, Xiaofeng Wang, Longxiang Tao, Quan Chen, Yunpeng Bian, Xiaoxuan He, Yikang Liu, Weiping Ding, Yongqiang Yu, Bensheng Qiu
RATIONALE AND OBJECTIVES: Chemotherapy has many side effects on breast cancer patients, including cognition and other brain functions impairment, which can be studied using functional magnetic resonance imaging (fMRI). Our study aimed at investigating the executive function alternations of breast cancer patients after chemotherapy using resting-state fMRI. MATERIALS AND METHODS: This study included 32 breast cancer patients (BC group) and 24 control subjects (HC group)...
October 2016: Academic Radiology
Yin Ting Cheung, Michelle N Edelmann, Daniel A Mulrooney, Daniel M Green, Wassim Chemaitilly, Neena John, Leslie L Robison, Melissa M Hudson, Kevin R Krull
BACKGROUND: Hyperuricemia is implicated in cardiovascular and cerebrovascular diseases. This study evaluated associations between uric acid (UA), cardiovascular health, and neurocognitive function in adolescent and adult survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. METHODS: 126 adolescent [mean (SD) age 14.6 (5.0); 7.8 (1.7) years postdiagnosis] and 226 adult survivors [age 25.4 (4.2) years; 18.1 (4.4) years postdiagnosis] completed comprehensive neurocognitive testing...
August 2016: Cancer Epidemiology, Biomarkers & Prevention
Kevin R Krull, Yin Ting Cheung, Wei Liu, Slim Fellah, Wilburn E Reddick, Tara M Brinkman, Cara Kimberg, Robert Ogg, Deokumar Srivastava, Ching-Hon Pui, Leslie L Robison, Melissa M Hudson
PURPOSE: To examine associations among methotrexate pharmacodynamics, neuroimaging, and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy-only protocol. PATIENTS AND METHODS: This longitudinal study linked pharmacokinetic assays collected during therapy to neurocognitive and brain imaging outcomes during long-term follow-up. A total of 218 (72.2%) of 302 eligible long-term survivors were recruited for outcome studies when they were more than 5 years post-diagnosis and older than 8 years of age...
August 1, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Nisha Narayanan, Lakshmi V Nair, Varsha Karunakaran, Manu M Joseph, Jyothi B Nair, Ramya A N, Ramapurath S Jayasree, Kaustabh Kumar Maiti
Herein, we have examined distinctive structural and functional variations of cellular components during apoptotic cell death induced by a targeted theranostic nanoprobe, MMP-SQ@GNR@LAH-DOX, which acted as a SERS "on/off" probe in the presence of a MMP protease and executed synergistic photothermal chemotherapy, as reflected by the SERS fingerprinting, corresponding to the phosphodiester backbone of DNA.
June 2, 2016: Nanoscale
Mary E Reyland, David N M Jones
The serine-threonine protein kinase, protein kinase C-δ (PKCδ), is emerging as a bi-functional regulator of cell death and proliferation. Studies in PKCδ-/- mice have confirmed a pro-apoptotic role for this kinase in response to DNA damage and a tumor promoter role in some oncogenic contexts. In non-transformed cells, inhibition of PKCδ suppresses the release of cytochrome c and caspase activation, indicating a function upstream of apoptotic pathways. Data from PKCδ-/- mice demonstrate a role for PKCδ in the execution of DNA damage-induced and physiologic apoptosis...
September 2016: Pharmacology & Therapeutics
Jose Felix Moruno Manchon, Yuri Dabaghian, Ndidi-Ese Uzor, Shelli R Kesler, Jeffrey S Wefel, Andrey S Tsvetkov
Neurotoxicity may occur in cancer patients and survivors during or after chemotherapy. Cognitive deficits associated with neurotoxicity can be subtle or disabling and frequently include disturbances in memory, attention, executive function and processing speed. Searching for pathways altered by anti-cancer treatments in cultured primary neurons, we discovered that doxorubicin, a commonly used anti-neoplastic drug, significantly decreased neuronal survival. The drug promoted the formation of DNA double-strand breaks in primary neurons and reduced synaptic and neurite density...
2016: Scientific Reports
Hui Miao, Jingjing Li, Sheng Hu, Xiaoxuan He, Savannah C Partridge, Jian Ren, Yunpeng Bian, Yongqiang Yu, Bensheng Qiu
BACKGROUND: Chemotherapy, a prominent treatment for breast cancer (BC), can have detrimental side effects on the patient's cognitive functions including the executive function. However, the neurophysiological mechanism of the cognitive impairment remains unclear. OBJECTIVE: The purpose of this study is to explore long-term chemotherapy-related functional connectivity changes using fMRI and the relationship between the connectivity changes and the executive function impairment in breast cancer patients...
June 2016: European Journal of Radiology
Debra E Lyon, Ronald Cohen, Huaihou Chen, Debra L Kelly, Angela Starkweather, Hyo-Chol Ahn, Colleen K Jackson-Cook
PURPOSE: Cognitive dysfunction in women with breast cancer continues to be an area of intense research interest. The prevalence, severity, timing, and cognitive domains that are most affected, as well as the contribution of cancer and its treatments to cognition, remain unresolved. Thus, longitudinal studies are needed that examine cognitive function during different stages of breast cancer treatment and survivorship. This longitudinal trial followed women with early-stage breast cancer, prior to chemotherapy through 2 years survivorship...
July 2016: Journal of Cancer Research and Clinical Oncology
Denise D Correa, Jaya Satagopan, Kenneth Cheung, Arshi K Arora, Maria Kryza-Lacombe, Youming Xu, Sasan Karimi, John Lyo, Lisa M DeAngelis, Irene Orlow
BACKGROUND: Cognitive dysfunction is common among patients with brain tumors and can be associated with the disease and treatment with radiotherapy and chemotherapy. However, little is known about genetic risk factors that may moderate the vulnerability for developing cognitive dysfunction. In this study, we examined the association of single nucleotide polymorphisms (SNPs) in the catechol-O-methyl transferase (COMT), brain-derived neurotrophic factor (BDNF), and dystrobrevin-binding protein 1 (DTNBP1) genes with cognitive functions and neuroimaging outcomes in patients with brain tumors...
October 2016: Neuro-oncology
Tami D John, Leonard S Sender, Daniela A Bota
INTRODUCTION: The development of complex cognitive functions including executive functions occurs during adolescence and early young adulthood. Survivors of cancers diagnosed during adolescence and young adulthood (AYA) may be at specific risk for chemotherapy-associated cognitive impairment; however, little data are available that specifically examine long-term cognitive outcomes in the AYA-onset cancer survivor population. METHODS: A literature search was conducted between January 1991 to December 2015 using a variety of search terms pertaining to the AYA-onset cancer population and cognitive outcomes...
September 2016: Journal of Adolescent and Young Adult Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"